186 related articles for article (PubMed ID: 14688462)
21. STI571: a magic bullet?
Verweij J; Judson I; van Oosterom A
Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
[No Abstract] [Full Text] [Related]
22. [Novel medical treatment modalities in hematology].
Hasselbalch HC; Birgens H; Dufva IH; Dalseg AM; Brown Pde N; Jensen MK; Vangsted A
Ugeskr Laeger; 2008 Jun; 170(24):2115-9. PubMed ID: 18565291
[TBL] [Abstract][Full Text] [Related]
23. STI571 (imatinib mesylate): the tale of a targeted therapy.
Thambi P; Sausville EA
Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
25. STI571 (Gleevec) as a paradigm for cancer therapy.
Druker BJ
Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Hernández-Boluda JC; Cervantes F
Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
[TBL] [Abstract][Full Text] [Related]
27. Beyond Herceptin and Gleevec.
Fischer OM; Streit S; Hart S; Ullrich A
Curr Opin Chem Biol; 2003 Aug; 7(4):490-5. PubMed ID: 12941424
[TBL] [Abstract][Full Text] [Related]
28. [STI571: a summary of targeted therapy].
Czyz M; Jakubowska J
Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
[TBL] [Abstract][Full Text] [Related]
29. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
30. STI571 as a targeted therapy for CML.
O'Dwyer ME; Mauro MJ; Druker BJ
Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
Nadal E; Olavarria E
Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; Ackermann H; May A; Hambek M; Knecht R
J Cancer Res Clin Oncol; 2009 Mar; 135(3):387-93. PubMed ID: 18830627
[TBL] [Abstract][Full Text] [Related]
33. Researchers optimistic about sea change in cancer treatment.
Stephenson J
JAMA; 2001 Jun; 285(22):2841-2. PubMed ID: 11401587
[No Abstract] [Full Text] [Related]
34. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
[TBL] [Abstract][Full Text] [Related]
35. [EGFR/HER1: a target life].
Viel E; Curtit E; Mansi L; Vignot S
Bull Cancer; 2012 Feb; 99(2):181-9. PubMed ID: 21684835
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy and hematological malignancy.
Armitage JO
Target Oncol; 2009 Jan; 4(1):1-2. PubMed ID: 19343296
[No Abstract] [Full Text] [Related]
37. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
38. [Tyrosine kinases. New target of anticancer therapy].
Majsterek I; Pytel D; Błasiak J
Postepy Biochem; 2005; 51(3):251-60. PubMed ID: 16381169
[TBL] [Abstract][Full Text] [Related]
39. New agents in cancer clinical trials.
Adams J; Elliott PJ
Oncogene; 2000 Dec; 19(56):6687-92. PubMed ID: 11426656
[No Abstract] [Full Text] [Related]
40. Imatinib mesylate, the first molecularly targeted gene suppressor.
Pindolia VK; Zarowitz BJ
Pharmacotherapy; 2002 Oct; 22(10):1249-65. PubMed ID: 12389876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
